A comparative review on conventional and advanced ocular drug delivery formulations

International Journal of PharmTech Research

Volumn 2, Issue 1, 2010, Pages 668-674

  Rajasekaran, A ^a   Kumaran, K S G Arul ^a   Preetha, J Padma ^a   Karthika, K ^a  

^a KMCH COLLEGE OF PHARMACY   (India)

Author keywords

Collagen shields; Conventional formulation; Minidisc and NODS; Ocufit; Ocular drug delivery; Ocusert; SODI

Indexed keywords

ADRENALIN; CYCLODEXTRIN; PHENYLEPHRINE; PILOCARPINE; PRODRUG; TIMOLOL;

CONTROLLED STUDY; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; EMULSION; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; IONIC STRENGTH; REVIEW; SUSTAINED DRUG RELEASE; TEMPERATURE SENSITIVITY;

EID: 77953433789     PISSN: None     EISSN: 09744304     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. ST Edition(2005); 82-96
2. Manoj A.Bagool, Topical ocular drug delivery review, Indian drugs (1993);31(10); 51
3. ST Edition(2005); 82-96
4. Marco Fabrizio Saettone, Lotta Salminen, Ocular inserts for topical delivery, Turkey J Pharm Sci1995; 95-106
5. Lee V.H; Robinson J.R, Ocular drug delivery system, Biopharm J of Ocular Pharmacol 1986 ;2(1);84-86
6. Robinson J.R, "Ocular drug delivery system",1989;5(12); 839
7. Jain N.K, Menqui S.A and Deshpande S.G. " Controlled and Novel Drug Delivery" , CBS publishers; New Delhi;1ST Edition(2005); 82
8. Davios, Davies Clin, Exp, Pharmasol. Physiol., 90W. 27, 558
9. Durrani, A.M., Farr, S.J. and Kellaway. I.W., J. Pharm. Pharmacol., 1995 ;( 47); 581
10. Gazayerly, E.L., Omaima. N. and Hikal. A H., Int. J. Pharm. 1997; (158);121
11. Hui. H.W. and Robinson, J.R., Int. J. Pharm., 1985; (26); 203
12. Kamal S.Rathore, Dr.Nema.R.K, "Glaucoma: a review" published on-line at www. Earticles online .com (Jan4, 2009)
13. Kaur, I.P. and Smitha. R., Drug Develop. Ind. Pharm., 2002; (28); 353
14. Keistea, J.C., Cooper, E.R., Missel, P.J., Long, J.C. and Hager, D.F. J. Pharm. Sci, 1991; (80) 50.
15. Kumar, S., Haglund, B.O. and Himmelstein, K.J., J. Ocul. Pharmcol., 1994;(10)47.
16. Kurz, D. and Ciullla, T.A., Ophthalmic Clin. North. Amer.. 2002;(15)405.
17. Latorre F. and Nicolal, A.P., Drugs Exp, Clin, Res.. 1998; (24)153.
18. Lee, V.H.L. and Robinson, J.R., J. Ocul. Pharmacol., 1986; (2) 67.
19. Lin. H.R. and Sung. K.C., J. Contol. release, 2000;(69); 379.
20. lnduPal. K. and Meenakshi, K., Drug Develop. Ind. Pharm.Sci, 2002; 473.
21. Marshall. W.S. and Klyee, S.D., J. Membrane Biol., 1983;(73); 275.
22. Marco Fabrizio Saettone, Lotta Salminen, Ocular inserts for topical delivery,1995; 95-106
23. erg A. Fischer, MSc, Thomas M, The future of Ocular drug delivery, email article at www.google.com
24. Shyamala Bhaskara P.V., Lakshmi, Topical Ocular drug deliver review, 2005;404-408
25. Shigeru kawakami.A, koyo Nishidaa, Takahiro mukaia, Controlled release and ocular absorption of tilisolol utilizing ophthalmic insert incorporated Lipophilic prodrugs, J. of Controlled release, 2001;852-868
26. Yung-Chi Leea, Jeffrey W,Design and evaluation the ocular insert containing phenyl-epicene and tropicamide to improve and enhance the bioavailability of the drug. Int.J.of Pharm., 1999 (182), 121-126
27. Dale meisner and Michael mezei, Liposome ocular delivery systems, 1995 , Available online from 22 December 1999 at www.sciencedirect.com.
28. ST edition;2005; 384-397.